ClinicalTrials.gg
Status unknownNCT05812482Updated Apr 13, 2023

Treatment of Urethral Stricture With Urethral Drug Ball

An interventional study of Drug balloon dilatation and Direct vision internal urethrotomy (DVIU) in Urethral Stricture Less Than 2 cm, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Status unknown at 1 site in China. Open to male participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Male
01

Study summary

To evaluate the safety and efficacy of urethral drug balloon catheter in the treatment of urethral stricture.

Read the detailed description

This is a prospective, multicenter, randomized controlled, and superiority study. The two groups were randomly selected into a total of 150 subjects (75 in the test group and 75 in the control group) according to 1:1. The test group was treated with urethral drug balloon catheter from Lepu Medical Technology (Beijing) Co.,Ltd., while the control group was treated with direct vision internal urethrotomy (DVIU).

All subjects were followed up at 1, 3 and 6 months post-procedure, and the efficacy of urethral drug balloon catheter will be evaluated with the success rate of operation at 6 months as the main end point. Observe the occurrence of complications and other indicators to make a reliable evaluation of the safety of urethral drug balloon catheter.

02

Conditions studied

  • Urethral Stricture Less Than 2 cm

Browse trials for

Keywords

  • Urethral stricture
03

In context

Urethral Stricture

72 studies on the registry are indexed under Urethral Stricture; 25 are open to participants now.

This study's planned enrollment of 150 is above the median of 60 across 56 interventional studies indexed under Urethral Stricture.

Browse Urethral Stricture studies →

Lead sponsor

Lepu Medical Technology (Beijing) Co., Ltd. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age ≥ 18 and ≤ 85 years old, male patients;

      1. Urethral stricture was confirmed by transurethral angiography, and the length of stricture was less than 2 cm;
      1. Maximum urine flow rate (Qmax)\<15 ml/s;
      1. There are obvious symptoms of urinary tract stricture such as slow urine rheology, difficulty in urination and incomplete urination;
      1. International Prostate Symptom Score (IPSS) ≥ 13;
      1. The guide wire must be able to pass through the stenosis segment;
      1. Patients who can understand the purpose of the trial, voluntarily participate in and sign the form, can independently complete effective questionnaires, and are willing to conduct clinical follow-up according to the research requirements.

Exclusion criteria

Exclusion Criteria:

    1. Patients with multiple stenotic lesions;

      1. Patients with a history of allergy to paclitaxel and contrast agents, or patients undergoing treatment with drugs that may antagonize paclitaxel;
      1. Patients who have undergone hypospadias repair, urethroplasty, stricture expansion or incision in the past 3 months;
      1. Urethral stricture caused by the following causes: bacterial urethritis, untreated gonorrhea, lichen sclerosus or dry glans obliterans;
      1. There are other diseases that can cause lower urinary tract symptoms, such as overactivity of bladder, neurogenic bladder dysfunction, etc;
      1. There are adverse factors for catheter insertion;
      1. Patients with artificial penis or urethral sphincter, or urethral or prostate stent;
      1. Patients who have been diagnosed with urethra cancer, bladder cancer cancer or prostate cancer, or who have experienced pelvic radiotherapy in the past 2 years;
      1. For patients with severe renal insufficiency, their serum creatinine is more than 2.5mg/dL or they are undergoing hemodialysis;
      1. Patients with severe lung disease, cardiovascular disease, coagulation dysfunction and of anesthesia;
      1. Patients with poor control of diabetes (>8.0%);
      1. Patients with active urinary stones in the past 6 months;
      1. Patients who are not suitable for direct vision internal urethrotomy;
      1. Patients with pregnancy preparation plan;
      1. Patients who are participating in clinical trials of other drugs or medical devices and have not reached their main endpoint;
      1. Patients who cannot participate in the clinical trial due to other reasons considered by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Test group

    The test arm will be the treated by Drug Balloon

    Procedure: Drug balloon dilatation

  • Other
    Control group

    The control arm will be treated by Direct vision internal urethrotomy (DVIU)

    Procedure: Direct vision internal urethrotomy (DVIU)

Interventions

  • ProcedureDrug balloon dilatation

    The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated

  • ProcedureDirect vision internal urethrotomy (DVIU)

    A control subject will choose DVIU surgery until the desired effect is achieved

06

What researchers measure

Primary outcomes

  1. Procedural success

    no reoperation or instrument intervention is required, and 16F bladder flexible mirror or 16F catheter can pass through the stenosis

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Change in the International Prostate Symptom Score (IPSS)

    Time frame: 1, 3 and 6months

  2. Change in the Quality of life index score (QOL)

    Time frame: 1, 3 and 6months

  3. Maximum urinary flow rate (Qmax)

    Time frame: 1 and 6 months post-procedure

  4. Residual urine volume (PVR)

    Time frame: 6 months post-procedure

  5. Postoperative complications

    bleeding, false passage formation, rectal injury, infection, etc

    Time frame: 1,3,6 months post-procedure

  6. Number of re-interventions after operation

    Time frame: 1, 3, 6 months post-procedure

07

Study locations

1 of 1 sites recruiting
  • Beijing Hospital
    Beijing, Beijing 100005, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Oct 2024, 31 months after the start.

Of 24 interventional studies with no phase under Urethral Stricture, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Apr 13, 2023
StartActual
Mar 31, 2022
Primary completionEst.
Oct 31, 2024
CompletionEst.
Feb 28, 2025
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05812482
Responsible party
Sponsor
First posted
Apr 13, 2023
Start date
Mar 31, 2022
Primary completion
Oct 31, 2024 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
Apr 13, 2023

Study contacts

Ting Zhang
Contact
ting_zhang@lepumedical.com
010-80120666
Jianye Wang
Contact
wangjy@bjhmoh.cn
13901058760
Jianbing Li
study director · Beijing Tsinghua Changgeng Hospital
Jianbin Bi
study director · First Hospital of China Medical University
Qiang Fu
study director · Shanghai 6th People's Hospital
Shaogang Wang
study director · Tongji Hospital affiliated to Tongji Medical College HUST
Xiaoping Zhang
study director · Wuhan Union Hospital, China
Yuanjie Niu
study director · Tianjin Medical University Second Hospital
Jinjian Yang
study director · The First Affiliated Hospital of Zhengzhou University
Weijun Qin
study director · Air Force Medical University of PLA (the Fourth Military Medical University)
Lei Li
study director · First Affiliated Hospital Xi'an Jiaotong University
Deyi Luo
study director · West China School of Medicine of Sichuan University
Zhansong Zhou
study director · Southwest Hospital, China
Wei Yu
study director · Peking University First Hospital
Jianwei Wang
study director · Beijing Jishuitan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion